EU regulator recommends suspension India-tested drugs
The European Medicines Agency said the recommendation was based on findings from an inspection that raised concerns about how GVK conducted studies at the Hyderabad site on behalf of the pharmaceutical companies.

London: Europe's drug regulator said today it had recommended the suspension of a number of drugs which were approved on the basis of clinical studies conducted at GVK Biosciences in Hyderabad, India.[caption id="attachment_29715" align="alignleft" width="380"]
Representational image. Reuters[/caption]The European Medicines Agency said the recommendation was based on findings from an inspection that raised concerns about how GVK conducted studies at the Hyderabad site on behalf of the pharmaceutical companies.The move follows a similar decision from state regulators in France, Germany, Belgium and Luxembourg in December to suspend the marketing approval of 25 generic drugs due to concerns over the quality of data from clinical trials conducted by the Indian firm.Reuters

Google burns cash for first time as AI spending pushes 2026 capex to $205 billion
Tesla sells more cars but makes less money: Why Musk’s AI pivot is squeezing profits
No premium queues, 30-minute target: What changes for Indian passport applicants in UAE
Bharat Forge, Flying Whales sign pact to develop 60-tonne airships for India’s defence logistics
Air India to cut Delhi-Toronto flight time by 3 hours, resume non-stop services from August 1

